血液生物标志物追踪记忆:面向阿尔茨海默病风险的早期检测、药物基因组学与老药新用
研究在男女精神科患者中开展纵向个体内研究,发现可追踪霍普金斯词语学习测验保持测量所反映短期记忆的血液基因表达标志物;经汇聚功能基因组学优先化并在独立队列验证其对状态短期记忆和未来认知受损神经心理测验的预测能力。最佳证据支持RAB7A、NPC2、TGFB1、GAP43、ARSB、PER1、GUSB、MAPT等基因作为血液标志物,并涉及LXR/RXR激活、神经炎症、动脉粥样硬化信号与淀粉样蛋白加工等通路。
要点
- 血液基因表达标志物可追踪精神科患者短期记忆,并预测未来认知受损。
- RAB7A、NPC2、TGFB1、GAP43、ARSB、PER1、GUSB、MAPT获人类功能证据支持。
- 部分标志物受抗抑郁药、锂盐和ω-3脂肪酸调控,并提示应激为早期风险因素。
核心结论
- 血液基因表达标志物可用于追踪精神科患者短期记忆并预测未来认知受损,为阿尔茨海默病风险早期检测与精准医学提供新途径。
研究设计与样本
- 在男女精神科患者中开展纵向个体内研究,以霍普金斯词语学习测验保持测量评估短期记忆。
- 用汇聚功能基因组学方法结合既往阿尔茨海默病证据对标志物优先化,并在独立队列验证其预测状态短期记忆和未来认知受损神经心理测验的能力。
主要发现
- 最佳总体证据支持RAB7A、NPC2、TGFB1、GAP43、ARSB、PER1、GUSB、MAPT作为新的人类血液功能标志物。
- GSK3B、PTGS2、APOE、BACE1、PSEN1、TREM2等已知阿尔茨海默病基因作为阳性对照,支持全基因组表达发现方法。
- 通路分析提示LXR/RXR激活、神经炎症、动脉粥样硬化信号与淀粉样蛋白加工参与。
- 多数顶级标志物也涉及其他精神障碍尤其是应激,为临床共病和应激作为早期促发/风险因素提供分子基础。
关键数值与推荐
- 短期记忆以霍普金斯词语学习测验中的保持测量评估。
- 标志物优先化采用汇聚功能基因组学方法,结合既往阿尔茨海默病证据。
- 部分标志物受抗抑郁药、锂盐和ω-3脂肪酸调控;生物信息学老药新用分析提示吡格列酮、左炔诺孕酮、沙索林、银杏内酯A和淫羊藿苷等候选。
临床怎么用
- 精神科患者可考虑用血液基因表达标志物辅助评估短期记忆障碍与未来认知受损风险。
- 标志物受抗抑郁药、锂盐和ω-3脂肪酸调控,提示药物基因组学指导的个体化预防与早期治疗潜力。
- 应激相关精神障碍患者可能是阿尔茨海默病早期风险监测的重点人群。
局限性
- 研究在精神科患者中开展,结论外推至一般人群需谨慎。
- 老药新用候选仅来自生物信息学分析,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Short-term memory dysfunction is a key early feature of Alzheimer's disease (AD). Psychiatric patients may be at higher risk for memory dysfunction and subsequent AD due to the negative effects of stress and depression on the brain. We carried out longitudinal within-subject studies in male and female psychiatric patients to discover blood gene expression biomarkers that track short term memory as measured by the retention measure in the Hopkins Verbal Learning Test. These biomarkers were subsequently prioritized with a convergent functional genomics approach using previous evidence in the field implicating them in AD. The top candidate biomarkers were then tested in an independent cohort for ability to predict state short-term memory, and trait future positive neuropsychological testing for cognitive impairment. The best overall evidence was for a series of new, as well as some previously known genes, which are now newly shown to have functional evidence in humans as blood biomarkers: RAB7A, NPC2, TGFB1, GAP43, ARSB, PER1, GUSB, and MAPT. Additional top blood biomarkers include GSK3B, PTGS2, APOE, BACE1, PSEN1, and TREM2, well known genes implicated in AD by previous brain and genetic studies, in humans and animal models, which serve as reassuring de facto positive controls for our whole-genome gene expression discovery approach. Biological pathway analyses implicate LXR/RXR activation, neuroinflammation, atherosclerosis signaling, and amyloid processing. Co-directionality of expression data provide new mechanistic insights that are consistent with a compensatory/scarring scenario for brain pathological changes. A majority of top biomarkers also have evidence for involvement in other psychiatric disorders, particularly stress, providing a molecular basis for clinical co-morbidity and for stress as an early precipitant/risk factor. Some of them are modulated by existing drugs, such as antidepressants, lithium and omega-3 fatty acids. Other drug and nutraceutical leads were identified through bioinformatic drug repurposing analyses (such as pioglitazone, levonorgestrel, salsolidine, ginkgolide A, and icariin). Our work contributes to the overall pathophysiological understanding of memory disorders and AD. It also opens new avenues for precision medicine- diagnostics (assement of risk) as well as early treatment (pharmacogenomically informed, personalized, and preventive).
引用
- Niculescu AB, Le-Niculescu H, Roseberry K, et al. Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2019. PMID: 31792364. doi:10.1038/s41380-019-0602-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。